1 / 8

EMCC ECCO ESMO 2011 GI CancerUpdates RESPECT Phase IIb Study

EMCC ECCO ESMO 2011 GI CancerUpdates RESPECT Phase IIb Study. Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October 20, 2011.

holt
Télécharger la présentation

EMCC ECCO ESMO 2011 GI CancerUpdates RESPECT Phase IIb Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EMCC ECCO ESMO 2011 GI CancerUpdates RESPECT Phase IIb Study Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October 20, 2011

  2. A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial Author: J Tabernero et al

  3. Study Design N=200 Primary Outcome: PFS Sorafenib 400 mg po BID + mFOLFOX6 R Placebo +mFOLFOX6 Untreated Metastatic Colorectal Cancer ECOG 0/1

  4. RESULTS

  5. GR 3/4 TOXICITY

  6. GR 3/4 TOXICITY

  7. STUDY COMMENTARY • The excess toxicity seen in the sorafenib arm had a major impact on the delivery of chemo in that arm • Sorafenib arm – no improvement in PFS, reduced RR and more toxic

  8. BOTTOM LINE FOR MEDICAL ONCOLOGISTS • Another VEGF TKI (along with PTK787, sunitininb and cediranib) that has failed to make an impact in the treatment of mCRC

More Related